211 related articles for article (PubMed ID: 36341357)
1. A CD8
Sun S; Zhi Z; Su Y; Sun J; Li Q
Front Immunol; 2022; 13():1039565. PubMed ID: 36341357
[TBL] [Abstract][Full Text] [Related]
2. Analysis of differential gene immune infiltration and clinical characteristics of skin cutaneous melanoma based on systems biology and drug repositioning methods to identify drug candidates for skin cutaneous melanoma.
Long S; Xu J; Huang H
Naunyn Schmiedebergs Arch Pharmacol; 2023 Oct; 396(10):2427-2447. PubMed ID: 37086280
[TBL] [Abstract][Full Text] [Related]
3. Lower Expression of GBP2 Associated With Less Immune Cell Infiltration and Poor Prognosis in Skin Cutaneous Melanoma (SKCM).
Zhang S; Chen K; Zhao Z; Zhang X; Xu L; Liu T; Yu S
J Immunother; 2022 Jul-Aug 01; 45(6):274-283. PubMed ID: 35543550
[TBL] [Abstract][Full Text] [Related]
4. Development and validation of an immune gene set-based prognostic signature in cutaneous melanoma.
Tian Q; Gao H; Zhao W; Zhou Y; Yang J
Future Oncol; 2021 Nov; 17(31):4115-4129. PubMed ID: 34291650
[TBL] [Abstract][Full Text] [Related]
5. Genes associated with cellular senescence favor melanoma prognosis by stimulating immune responses in tumor microenvironment.
Liang X; Lin X; Lin Z; Lin W; Peng Z; Wei S
Comput Biol Med; 2023 May; 158():106850. PubMed ID: 37031510
[TBL] [Abstract][Full Text] [Related]
6. Based on scRNA-seq and bulk RNA-seq to establish tumor immune microenvironment-associated signature of skin melanoma and predict immunotherapy response.
Li S; Zhao J; Wang G; Yao Q; Leng Z; Liu Q; Jiang J; Wang W
Arch Dermatol Res; 2024 May; 316(6):262. PubMed ID: 38795156
[TBL] [Abstract][Full Text] [Related]
7. Integrative lactylation and tumor microenvironment signature as prognostic and therapeutic biomarkers in skin cutaneous melanoma.
Zhu Y; Song B; Yang Z; Peng Y; Cui Z; Chen L; Song B
J Cancer Res Clin Oncol; 2023 Dec; 149(20):17897-17919. PubMed ID: 37955686
[TBL] [Abstract][Full Text] [Related]
8. Low expression of endoplasmic reticulum stress-related gene SERP1 is associated with poor prognosis and immune infiltration in skin cutaneous melanoma.
Fan Y; Liang X; Yu D
Aging (Albany NY); 2021 Oct; 13(19):23036-23071. PubMed ID: 34613934
[TBL] [Abstract][Full Text] [Related]
9. Predicting the clinical outcome of melanoma using an immune-related gene pairs signature.
Meng L; He X; Zhang X; Zhang X; Wei Y; Wu B; Li W; Li J; Xiao Y
PLoS One; 2020; 15(10):e0240331. PubMed ID: 33031392
[TBL] [Abstract][Full Text] [Related]
10. Development of a biomarker signature associated with anoikis to predict prognosis and immunotherapy response in melanoma.
Wu Z; Zhang R; Bao J; Yin M; Wang X
Arch Dermatol Res; 2024 May; 316(6):219. PubMed ID: 38787413
[TBL] [Abstract][Full Text] [Related]
11. 9-Gene Signature Correlated With CD8
Yan K; Lu Y; Yan Z; Wang Y
Front Immunol; 2021; 12():622563. PubMed ID: 34220795
[TBL] [Abstract][Full Text] [Related]
12. Exploring a 7-gene prognostic model based on ferroptosis for efficiently guiding immunotherapy in melanoma patients.
Zhang X; Ding C; Zhao Z
Adv Med Sci; 2022 Sep; 67(2):364-378. PubMed ID: 36155341
[TBL] [Abstract][Full Text] [Related]
13. Aspartate beta-hydroxylase domain containing 1 as a prognostic marker associated with immune infiltration in skin cutaneous melanoma.
Sun S; Deng M; Wen J; Chen X; Xu J; Liu Y; Wan H; Wang J; Yan L; He Y; Xu Y
BMC Cancer; 2023 Mar; 23(1):292. PubMed ID: 37004045
[TBL] [Abstract][Full Text] [Related]
14. Development and validation of a novel T cell proliferation-related prognostic model for predicting survival and immunotherapy benefits in melanoma.
Chen J; Wang D; Chan S; Yang Q; Wang C; Wang X; Sun R; Gui Y; Yu S; Yang J; Zhang H; Zhang X; Tang K; Zhang H; Liu S
Aging (Albany NY); 2023 May; 15(10):4444-4464. PubMed ID: 37227816
[TBL] [Abstract][Full Text] [Related]
15. A Necroptosis-Related Gene Signature to Predict the Prognosis of Skin Cutaneous Melanoma.
Xie Y; Xu Z; Mei X; Shi W
Dis Markers; 2022; 2022():8232024. PubMed ID: 36438905
[TBL] [Abstract][Full Text] [Related]
16. FLG Is a Potential Biomarker of Prognosis and Immunotherapy in Skin Cutaneous Melanoma.
Wu S; Liang Y; Zang Q; Xing Z; Yin P; Sun R; Dai B
Appl Bionics Biomech; 2022; 2022():5160748. PubMed ID: 35607429
[TBL] [Abstract][Full Text] [Related]
17. Identification and validation of TME-related signatures to predict prognosis and response to anti-tumor therapies in skin cutaneous melanoma.
Lian W; Zheng X
Funct Integr Genomics; 2023 May; 23(2):153. PubMed ID: 37160578
[TBL] [Abstract][Full Text] [Related]
18. Combined signature of G protein-coupled receptors and tumor microenvironment provides a prognostic and therapeutic biomarker for skin cutaneous melanoma.
Song B; Wang K; Peng Y; Zhu Y; Cui Z; Chen L; Yu Z; Song B
J Cancer Res Clin Oncol; 2023 Dec; 149(20):18135-18160. PubMed ID: 38006451
[TBL] [Abstract][Full Text] [Related]
19. Comprehensive analysis of the prognosis and biological significance for IFIT family in skin cutaneous melanoma.
Jiang Y; Zhang C; Zhang J; Han D; Shi X
Int Immunopharmacol; 2021 Dec; 101(Pt A):108344. PubMed ID: 34763233
[TBL] [Abstract][Full Text] [Related]
20. Development of an IFNγ response-related signature for predicting the survival of cutaneous melanoma.
Hu B; Wei Q; Li X; Ju M; Wang L; Zhou C; Chen L; Li Z; Wei M; He M; Zhao L
Cancer Med; 2020 Nov; 9(21):8186-8201. PubMed ID: 32902917
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
